SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.9B
Q3 2021
Positions
88
Filings on Record
27
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Boxer Capital, LLC reported $2.9B in U.S.-listed holdings across 88 positions for Q3 2021.

Its largest position, MRTXEUR, represents 12.4% of the portfolio.

Compared with Q2 2021, the fund opened 13 new positions and exited 20.

Portfolio Metrics

Turnover
+20.3%
vs prior filed quarter
Top-10 Concentration
+48.6%
share of reported value
Largest Position
+12.4%
Mirati Therapeutics
New / Exited
13 / 20
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 72.5%Other: 14.4%ADR: 13.0%ETP: 0.1%Equity WRT: 0.0%
  • Common Stock · 72.5% · $2.1B
  • Other · 14.4% · $412M
  • ADR · 13.0% · $373M
  • ETP · 0.1% · $3M
  • Equity WRT · 0.0% · $683,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TYRATYRA BIOSCIENCES INCNEW+6.32M6.32M+$111M$111M
TNGXTANGO THERAPEUTICS INCNEW+6.87M6.87M+$89M$89M
2655787DBLUEPRINT MEDICINES CORPNEW+425.0K425.0K+$44M$44M
FULCFULCRUM THERAPEUTICS INCNEW+1.25M1.25M+$35M$35M
TURNING POINT THERAPEUTICS INCNEW+525.0K525.0K+$35M$35M
NUVLNUVALENT INCNEW+1.21M1.21M+$27M$27M
IOVAIOVANCE BIOTHERAPETUICS INCNEW+1.10M1.10M+$27M$27M
PROTHENA CORP PLCNEW+300.0K300.0K+$21M$21M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM12.36%$354M2.00M
2ONCBEIGENE LTDhistory →SPONSORED ADR9.69%$277M764.2K
3SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM4.60%$132M2.08M
42662247DITEOS THERAPEUTICS INChistory →COM4.10%$117M4.35M
5TYRATYRA BIOSCIENCES INChistory →COM3.88%$111M6.32M
6RVMDREVOLUTION MEDICINES INChistory →COM3.35%$96M3.48M
7TNGXTANGO THERAPEUTICS INChistory →COM3.10%$89M6.87M
8CYTKCYTOKINETICS INChistory →COM NEW2.62%$75M2.10M
9RCUSARCUS BIOSCIENCES INChistory →COM2.54%$73M2.08M
10PMVPPMV PHARMACEUTICALS INChistory →COM2.36%$68M2.27M
11IDYAIDEAYA BIOSCIENCES INChistory →COM1.96%$56M2.20M
12ARGXARGENX SEhistory →SPONSORED ADR1.80%$52M170.9K
13CONNECT BIOPHARMA HLDGS LTDADS1.76%$50M2.08M
14SG7SAGE THERAPEUTICS INChistory →COM1.69%$48M1.09M
15RCKTROCKET PHARMACEUTICALS INChistory →COM1.53%$44M1.47M
16SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.53%$44M2.29M
172655787DBLUEPRINT MEDICINES CORPhistory →COM1.53%$44M425.0K
18NUVBNUVATION BIO INChistory →COM CL A1.51%$43M4.34M
19KNTEUSDKINNATE BIOPHARMA INChistory →COM1.49%$43M1.85M
20MERUS N VCOM1.46%$42M1.90M
21RLAYRELAY THERAPEUTICS INChistory →COM1.42%$41M1.29M
22DBV TECHNOLOGIES S ASPONSORED ADR1.29%$37M7.53M
23NRIXNURIX THERAPEUTICS INChistory →COM1.28%$37M1.22M
24FULCFULCRUM THERAPEUTICS INChistory →COM1.23%$35M1.25M
25ANABANAPTYSBIO INChistory →COM1.23%$35M1.30M
26TURNING POINT THERAPEUTICS INCCOM1.22%$35M525.0K
27GOSSGOSSAMER BIO INChistory →COM1.08%$31M2.46M
28DAWNGBXDAY ONE BIOPHARMACEUTICALS INChistory →COM0.99%$28M1.19M
29RNAGBPAVIDITY BIOSCIENCES INChistory →COM0.96%$28M1.12M
30MARINUS PHARMACEUTICALS INCCOM NEW0.95%$27M2.40M
31NUVLNUVALENT INChistory →COM0.95%$27M1.21M
32IOVAIOVANCE BIOTHERAPETUICS INChistory →COM0.95%$27M1.10M
33BMEABIOMEA FUSION INChistory →COM CL A0.87%$25M2.09M
34CGEMCULLINAN ONCOLOGY INChistory →COM0.85%$24M1.07M
35ALIGOS THERAPEUTICSCOM0.83%$24M1.53M
36GH RESEARCH PLCORDINARY SHARES0.78%$22M1.01M
37260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS0.78%$22M1.33M
38AM6AMICUS THERAPEUTICS INChistory →COM0.78%$22M2.33M
39PROTHENA CORP PLCSHS0.75%$21M300.0K
40BCABGBPBIOATLA INChistory →COM0.71%$20M686.3K
41KURAKURA ONCOLOGY INC.history →COM0.69%$20M1.05M
42CABACABALETTA BIO INChistory →COM0.68%$19M1.60M
43POINT BIOPHARMA GLOBAL INCCOM0.67%$19M2.50M
44PASSAGE BIO INCCOM0.67%$19M1.93M
45AKROAKERO THERAPEUTICS INChistory →COM0.65%$19M831.5K
46BLUBELLUS HEALTH INChistory →COM NEW0.64%$18M2.98M
47RAIN THERAPEUTICS INCCOM0.61%$18M1.18M
48BDTXBLACK DIAMOND THERAPEUTICS INChistory →COM0.60%$17M2.01M
4932WCODIAK BIOSCIENCES INChistory →COM0.59%$17M1.03M
50SPRYSILVERBACK THERAPEUTICS INChistory →COM0.58%$17M1.68M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.